Skip to main content

Raise Your Profile

Whether you are looking to attract a new business client, investment and partnering deal flow or talent, among other goals, One Nucleus offers a wide range of opportunities to raise your profile to our members and to the Greater Cambridge cluster in particular.
Raise Your Profile
  • Discounts for Members

    Discounts for Members

    Members can take advantage of discounts on a wide range of products and services to maximise their return on the member subscription, often recovering multiples of the fees paid. Receive discounted rates on laboratory supplies, services, key industry events and more.
    Learn more
  • Connect with Our Network

    Connect with Our Network

    A key advantage to any company joining One Nucleus is the ability to connect to potential partners, investors, service providers, clients and their peers for knowledge-sharing. We do this through our varied range of informative networking events, which tend to be situated throughout Cambridge and London.
    Learn more
  • Build the Best Teams

    Build the Best Teams

    One Nucleus recognises that a company’s employees are its most valuable asset and the competition for talented and skilled employees has never been fiercer in the region’s life science sector. One Nucleus offers a range of services and engagement opportunities in this critical area to help support our members and maintain the reputation of the sector.
    Learn more

Events

Connecting and meeting with business partners, fellow innovators and key advisers is a vital part of everyone's endeavours since it enables knowledge exchange and onward contact for mutual and collective success. Complementing the wider One Nucleus support activities our portfolio of events is designed to meet the needs of our network in terms of content, format, timing, peer-to-peer engagements and modes of delivery.
  • Events
  • Events
  • Events
  • Events

Membership Overview

With Gold and Silver membership options, our 400 company members and their staff can benefit from a wide variety of savings, profiling opportunities, and more.
  • Membership

About One Nucleus

One Nucleus is a not-for-profit Life Sciences & Healthcare membership organisation headquartered in Cambridge. We support institutions, companies and individuals in the Life Sciences sector providing local, UK-wide and international connectivity. 
  • About

Innovations in Organoid Culture: Techniques, Tools, and Applications

Corning Scientific Webinar
Organoids are 3D cellular models derived from pluripotent and adult stem cells, that mimic specific organs or tissues. Growth factors and extracellular matrices (ECM) support their self-renewal and differentiation. Used for various applications, including organ and tissue characterization, patient-derived organoids offer accurate models for personalized treatment, better representing the in vivo microenvironment compared to 2D cultures.

Coulter Partners strengthens ICR Healthcare’s senior team in Europe with Partner placement

London, January 28, 2025 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for ICR Healthcare and is pleased to announce the placement of Sarah Elton-Farr as Partner, effective April 2025. 

Cancer Research Horizons partners with Lifebit to maximise the impact of research data

Cancer Research Horizons has joined Lifebit’s Federated Data Network to help maximise the impact of data generated through Cancer Research UK-funded research.

This federated network leverages Lifebit’s cutting-edge Platform to ensure secure access to standardised datasets of millions of cancer patients from multiple international institutions for use in secure, large-scale cross-cohort analyses.

Pharmaron DMPK Webinar #25: Optimizing Method Development and Validation of Bioanalytical Assays for Challenging Chemical Constructs

Find out more about 𝐛𝐢𝐨𝐚𝐧𝐚𝐥𝐲𝐭𝐢𝐜𝐚𝐥 𝐚𝐬𝐬𝐚𝐲𝐬 in our upcoming webinar scheduled for Thursday, February 27 at 8am PT/11am ET/4pm GMT.

Join experts Hermes Licea-Perez, Jing Lai and Scott Summerfield who will be discussing the analytical challenges associated with the LC-MS bioanalysis of low molecular weight molecules (<200 amu) often associated with metabolomic measurements and analysis of biomarkers and metabolic products of drug biotransformations.

By registering once, you will have access to and receive updates for each webinar in the series.

BCA Spring Meeting 2025

The upcoming BCA Spring Meeting will focus on the theme “Learning from Others”, emphasizing the importance of collaboration in the current research environment to interact and work together to get the best data or to develop a deeper understanding of science.
The field of Crystallography supports research across various disciplines, and this will be celebrated at the upcoming Spring Meeting.

Plenary Speakers:
- John Helliwell (University of Manchester)
- Lucia Maini (University of Bologna)
- Robert Palgrave (UCL)
- Elton Zeqiraj (University of Leeds)

UK Life Sciences: Funding, Collaboration and AI Adoption Will Be Key to Success in 2025

RSM UK’s co-leads of life sciences, Laragh Jeanroy and Graham Bond, highlight three key themes dominating the sector in 2025:

Tighter funding
The value of private equity (PE) buyouts in the UK life sciences sector jumped from £778m in 2023 to £5.3bn in 2024, according to Pitchbook. However, the number of deals has remained fairly steady over the years, increasing from 10 in 2023 to 13 in 2024. A large proportion of PE and venture capital investment in the sector focused on traditional pharmaceuticals last year.

Cancer Research UK, Cytovation and the Norwegian Cancer Society collaborate to advance treatment for rare cancer

Cancer Research UK, Cytovation and the Norwegian Cancer Society have signed an agreement to bring Cytovation’s lead asset, CY-101, into a multi-national Phase 2 clinical trial for patients with adrenocortical carcinoma (ACC).

This rare and aggressive cancer, which affects the adrenal glands, has limited treatment options and an urgent need for new therapies.

Subscribe to